Current Edition

The Anticipated Clinical Effect of the new Alzheimer Drug ANAVEX PLUS

in a Predictive Humanised Cortical Cognitive Model for Alzheimer’s Disease
ANAVEX PLUS, the proprietary combination of ANAVEX 2-73 (AV2-73) with donepezil, the most prescribed Alzheimer’s drug, combines cholinergic pharmacology with muscarinic and sigma-1 receptor activity and can potentially combine symptomatic, neuroprotective and potentially disease-modifying properties, as illustrated in a paper by C. Missling of Anavex Life Sciences, T. Maurice of INSERM U710, University of Montpellier 2, France, A. Spiros of In Silico Biosciences, Lexington, MA, P. Roberts of OHSU, Portland, OR, and H. Geerts of University of Pennsylvania, PA. 
http://ipimediaworld.com/wp-content/uploads/2014/03/the-anticipated…pdf.pdf